PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”)..

普林斯顿，新泽西州——（商业新闻短讯）——百时美施贵宝（纽约证券交易所：BMY）今天宣布，已成功完成对卡鲁纳治疗公司（“卡鲁纳”）的收购。随着收购的完成，卡鲁纳的股票已停止在纳斯达克全球精选市场交易，卡鲁纳现在是百时美施贵宝（“BMS”）的全资子公司。

“We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Importantly, this transaction aligns with our commitment to strengthening BMS’s growth profile in the latter half of the decade and beyond.

Bristol-Myers Squibb首席执行官ChrisBoerner博士说：“欢迎Karuna加入Bristol-Myers Squibb，我们很高兴扩大我们的神经科学投资组合。”。“重要的是，这项交易符合我们在本十年后半期及以后加强BMS增长状况的承诺。

We look forward to working with Karuna’s talented team to bring KarXT to patients with schizophrenia later this year.”.

我们期待着与卡鲁纳的天才团队合作，在今年晚些时候将KarXT带给精神分裂症患者。”

Through this transaction, BMS has added KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of action and a differentiated efficacy and safety profile, and Karuna’s early-stage and pre-clinical pipeline. KarXT has a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024 for the treatment of schizophrenia in adults.

通过这项交易，BMS增加了KarXT（xanomeline trospium），一种具有新作用机制和不同疗效和安全性的抗精神病药物，以及Karuna的早期和临床前管道。KarXT于2024年9月26日制定了《处方药使用费法案》（PDUFA），用于治疗成人精神分裂症。

KarXT is also in registrational trials both for adjunctive therapy to existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer’s disease, with potential to expand to additional indications, including Bipolar I disorder and Alzheimer’s disease agitation..

KarXT也在注册试验中，用于精神分裂症现有标准治疗药物的辅助治疗和阿尔茨海默病患者的精神病治疗，有可能扩展到其他适应症，包括双相I型障碍和阿尔茨海默病激越。

As previously disclosed, the transaction is expected to be dilutive to Bristol Myers Squibb’s non-GAAP diluted earnings per share by approximately $0.30 in 2024 from the financing cost of the transaction, which is primarily from a recently completed new debt issuance. Bristol Myers Squibb expects to offset the operational expenses of the transaction through continued disciplined resource allocation, cost efficiencies and portfolio prioritization.

如前所述，该交易的融资成本预计将在2024年稀释百时美施贵宝的非公认会计准则稀释每股收益约0.30美元，这主要来自最近完成的新债务发行。百时美施贵宝（Bristol-Myers Squibb）预计将通过持续有序的资源分配、成本效率和投资组合优先级来抵消交易的运营费用。

Bristol Myers Squibb’s cash flows and strong financial profile enable continued commitment to strong investment-grade credit ratings and investment for growth through business development opportunities and distributions to shareholders through ongoing dividends and share repurchases..

百时美施贵宝（Bristol-Myers Squibb）的现金流和强劲的财务状况使其能够通过业务发展机会和通过持续股息和股票回购向股东分配资金，继续致力于强大的投资级信用评级和投资增长。

The transaction will be accounted for as an asset acquisition resulting in an approximately $12 billion one-time, non-deductible Acquired In-Process Research and Development (Acquired IPR&D) charge impacting both 2024 first quarter and full-year GAAP and non-GAAP EPS by approximately $5.93.

该交易将被视为资产收购，产生约120亿美元的一次性不可扣除的过程研究与开发（收购的知识产权与开发）费用，影响2024年第一季度和全年GAAP和非GAAP每股收益约5.93美元。

Consistent with past practice, Bristol Myers Squibb generally provides updates to its financial outlook once each quarter. When considering Bristol Myers Squibb’s financial outlook issued on February 2, 2024, investors and analysts should take into account the impacts outlined above. Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024..

与过去的做法一致，百时美施贵宝通常每季度更新一次财务前景。在考虑Bristol-Myers Squibb于2024年2月2日发布的财务展望时，投资者和分析师应考虑上述影响。Bristol-Myers Squibb将于2024年4月25日发布2024年第一季度财报，届时将更新其财务前景。

Advisors

顾问

Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel. Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Karuna, and Simpson Thacher & Bartlett LLP is serving as legal counsel.

Gordon Dyal&Co.和Citi担任百时美施贵宝的财务顾问，Covington&Burling LLP担任法律顾问。高盛公司（Goldman Sachs&Co.LLC）担任卡鲁纳（Karuna）的独家财务顾问，辛普森·撒切尔（Simpson Thacher&Bartlett）律师事务所（Simpson Thacher&Bartlett LLP）担任法律顾问。

About Bristol Myers Squibb

关于百时美施贵宝

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram..

百时美施贵宝是一家全球生物制药公司，其使命是发现、开发和提供创新药物，帮助患者战胜严重疾病。有关百时美施贵宝的更多信息，请访问BMS.com或在LinkedIn、Twitter、YouTube、Facebook和Instagram上关注我们。